Precigen, Inc. (PGEN)
PGEN moved a median of 0.00% 30 minutes after news, and 0.00% by the close. How PGEN actually reacts to news — the realized, point-in-time move the market made, measured across 288 labeled events over the last three years with zero look-ahead.
PGEN’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.01% | 51% | 288 |
| 30-min | 0.00% | 51% | 288 |
| 60-min | +0.41% | 56% | 288 |
| to close | 0.00% | 48% | 285 |
| Middle 50% of PGEN reactions | -1.82% to +1.81% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 288 |
Half of all Precigen, Inc. news events land between -1.82% and +1.81% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How PGEN reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 10 | +1.24% | 60% | +2.00% |
| Rating reiterations | 47 | +0.93% | 57% | +1.63% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 4 further classes were observed with fewer than 10 measured events and are not published. See how PGEN ranks against every other measured name →
That’s how PGEN usually reacts — get an email when it moves on news →Email me when PGEN moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to PGEN's baseline. Nothing else.
Recent PGEN events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Precigen Receives FDA Platform Technology Designation for AdenoVerse Platform | Press release | PR Newswire | -0.89% | -1.79% | |
| Precigen's Strong Second Quarter Signals Significant Growth, Validates AdenoVerse Platform; PRGN-2009 Advances in HPV-Driven Cancers | Press release | ACCESS Newswire | +0.75% | -0.14% | |
| Form 10-Q PRECIGEN, INC. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -3.53% | -2.68% | |
| Form 8-K PRECIGEN, INC. For: Aug 04 | SEC filing · Form 8-K | SEC EDGAR | -3.53% | -2.68% | |
| Precigen Reports Second Quarter 2026 Financial Results Highlighted by Accelerating PAPZIMEOS Revenue Growth | Press release | PR Newswire | -3.53% | -2.68% | |
| Precigen to Announce Second Quarter 2026 Financial Results and Provide Business Updates on August 4 | Press release | PR Newswire | +0.78% | +7.23% | |
| Form 8-K PRECIGEN, INC. For: Jun 18 | SEC filing · Form 8-K | SEC EDGAR | -1.25% | -1.60% | |
| Precigen Gains Advantage as PAPZIMEOS Granted Orphan Drug Exclusivity by FDA; Long-Term Data From Clinical Study Encouraging | Press release | ACCESS Newswire | -0.43% | +4.35% | |
| Precigen and the Recurrent Respiratory Papillomatosis Foundation Recognize International RRP Awareness Day by Elevating Patient and Community Voices | Press release | PR Newswire | -1.74% | +16.45% | |
| Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years | Press release | PR Newswire | +0.35% | -3.74% | |
| Precigen Receives Orphan Drug Exclusivity for PAPZIMEOS (zopapogene imadenovec-drba) in the United States | Press release | PR Newswire | -0.24% | +3.77% | |
| Precigen to Participate in Fireside Chats with J.P. Morgan and at the Goldman Sachs 47th Annual Global Healthcare Conference | Press release | PR Newswire | +0.70% | -1.17% | |
| Form 10-Q PRECIGEN, INC. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -3.49% | +0.44% | |
| Form 8-K PRECIGEN, INC. For: May 13 | SEC filing · Form 8-K | SEC EDGAR | -3.49% | +0.44% | |
| Precigen Reports First Quarter 2026 Financial Results and Business Updates | Press release | PR Newswire | -3.49% | +0.44% | |
| Precigen to Announce First Quarter 2026 Financial Results and Provide Business Updates on May 13 | Press release | PR Newswire | +0.00% | +0.96% | |
| Form ARS PRECIGEN, INC. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.36% | -1.21% | |
| Form DEF 14A PRECIGEN, INC. For: Jun 18 | SEC filing · Form DEF | SEC EDGAR | +0.36% | -1.21% | |
| Form DEFA14A PRECIGEN, INC. | SEC filing · Form DEFA14A | SEC EDGAR | +0.36% | -1.21% | |
| Precigen Reports 'Robust Uptake' of New Drug for Rare Respiratory Disease; First Quarter Revenue Expected to Top $18 Million | Press release | ACCESS Newswire | +0.24% | +0.98% | |
| Precigen to Participate in a Fireside Chat with H.C. Wainwright on March 31 | Press release | PR Newswire | -1.52% | -9.97% | |
| Form 10-K PRECIGEN, INC. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +2.20% | -4.66% | |
| Form 8-K PRECIGEN, INC. For: Mar 25 | SEC filing · Form 8-K | SEC EDGAR | +2.20% | -4.66% | |
| Precigen Reports Full Year 2025 Financial Results and Business Updates | Press release | PR Newswire | +2.20% | -4.66% | |
| Precigen to Announce Full Year 2025 Financial Results and Provide Business Updates on March 25 | Press release | PR Newswire | -1.61% | -3.81% | |
| New Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis | Press release | PR Newswire | -0.73% | +0.92% | |
| Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference | Press release | PR Newswire | -0.66% | -8.72% | |
| Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference | Press release | PR Newswire | +0.24% | +9.11% | |
| Precigen to Announce Third Quarter 2025 Financial Results and Provide Business Updates on November 13 | Press release | PR Newswire | -0.51% | +0.00% | |
| Precigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recurrent Respiratory Papillomatosis | Press release | PR Newswire | -1.37% | -2.13% | |
| Form EFFECT PRECIGEN, INC. | SEC filing · Form EFFECT | SEC EDGAR | +2.42% | +2.94% | |
| Form 8-K PRECIGEN, INC. For: Sep 15 | SEC filing · Form 8-K | SEC EDGAR | +3.13% | -1.04% | |
| Form 8-K PRECIGEN, INC. For: Sep 03 | SEC filing · Form 8-K | SEC EDGAR | +0.94% | -1.25% | |
| Precigen Announces Up to $125 Million Non-Dilutive Financing | Press release | PR Newswire | +0.94% | -1.25% | |
| Precigen to Participate in Upcoming Virtual Fireside Chats Hosted by Cantor and H.C. Wainwright | Press release | PR Newswire | +0.97% | -4.79% | |
| Form S-3 PRECIGEN, INC. | SEC filing · Form S-3 | SEC EDGAR | -2.55% | — | |
| Form 8-K PRECIGEN, INC. For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | +7.98% | — | |
| Form 8-K PRECIGEN, INC. For: Aug 18 | SEC filing · Form 8-K | SEC EDGAR | -5.56% | +2.43% | |
| Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis | Press release | PR Newswire | +5.43% | +13.95% | |
| Form 10-Q PRECIGEN, INC. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.52% | +4.37% | |
| Form 8-K PRECIGEN, INC. For: Jun 26 | SEC filing · Form 8-K | SEC EDGAR | -0.70% | +2.11% | |
| Form ARS PRECIGEN, INC. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -1.71% | -6.85% | |
| Form DEF 14A PRECIGEN, INC. For: Jun 26 | SEC filing · Form DEF | SEC EDGAR | -1.71% | -6.85% | |
| Form DEFA14A PRECIGEN, INC. | SEC filing · Form DEFA14A | SEC EDGAR | -1.71% | -6.85% | |
| Form 10-Q PRECIGEN, INC. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +3.54% | +3.15% | |
| Form 8-K PRECIGEN, INC. For: May 14 | SEC filing · Form 8-K | SEC EDGAR | +3.54% | +3.15% | |
| Precigen Reports First Quarter 2025 Financial Results and Business Updates | Press release | PR Newswire | +3.54% | +3.15% | |
| Form PRE 14A PRECIGEN, INC. For: Jun 26 | SEC filing · Form PRE | SEC EDGAR | -0.93% | -4.25% | |
| Form 10-K/A PRECIGEN, INC. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -0.65% | +0.00% | |
| Precigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11th | Press release | PR Newswire | -1.40% | -4.20% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the PGEN section they belong to.
Where else PGEN is measured.
PGEN earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Precigen, Inc.'s median reaction calculated?
Every labeled PGEN news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 288 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 51% of PGEN's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does PGEN's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.